Loading...
The impact of SARS-CoV-2 variants on IBD management
Segal, Jonathan P Kumar, Aditi Raine, Tim Lamb, Christopher A
Segal, Jonathan P
Kumar, Aditi
Raine, Tim
Lamb, Christopher A
Editors
Other contributors
Affiliation
Epub Date
Issue Date
2021-03-09
Submitted date
Subjects
Alternative
Abstract
The COVID-19 pandemic has revealed several challenges in inflammatory bowel disease (IBD) management. One of the initial key considerations was the effect of immunosuppression on COVID-19 incidence and outcomes, as well as on immunity after infection or vaccination.1, 2 With a rise in cases due to the emergence of SARS-CoV-2 variants, the question now is whether this information still applies.
Citation
Segal, J.P., Kumar, A., Raine, T., Lamb, C.A. and Brookes, M.J. (2021) The impact of SARS-CoV-2 variants on IBD management. The Lancet Gastroenterology and Hepatology, 6(5), pp. 343-344.
Publisher
Research Unit
PubMed ID
33711289 (pubmed)
PubMed Central ID
Embedded videos
Type
Journal article
Language
en
Description
This is an accepted manuscript of correspondence published by Elsevier on 09/03/2021, available online: https://doi.org/10.1016/S2468-1253(21)00075-3. The accepted version of the publication may differ from the final published version.
Series/Report no.
ISSN
2468-1253
EISSN
2468-1253